Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

gallae rhizoma 115.8mg,parameriae cortex 114.75mg,granati fructus cortex 115.8mg,cangli folium 57.9mg,boesenbergiae rhizome 114.75mg

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

green tea 1.2g containing paramenae cortex 0.24g,guazumate folium 0.24g,foeniculu fructus 0.08mg

Australia - English - Department of Health (Therapeutic Goods Administration)

medtronic australasia pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

karl storz endoscopy australia pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott vascular division of abbott medical australia pty ltd - 56284 - drug-eluting coronary artery stent, non-biodegradable-polymer-coated - stenting system for coronary arteries, supplied pre-loaded onto an angioplasty balloon catheter. the xience prime is intended to deliver and deploy a balloon-expandable, drug coated metal stent in the de novo and restenotic native coronary arteries. five different stent diameters in six different lengths are available. drug dose (micrograms)varies with stent size. the xience prime? everolimus eluting coronary stent system is indicated for improving coronary artery luminal diameter in the following: ? patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. ? for restoring coronary flow in patients experiencing acute myocardial infarction who present within 12 hours of symptom onset. ? for the treatment of patients with concomitant diabetes, acute coronary syndrome, dual vessel lesions (two lesions in two different epicardial vessels), lesions residing within small coronary vessels; lesions where treatment results in the jailing of side branches (lesions with a s

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott vascular division of abbott medical australia pty ltd - 56284 - drug-eluting coronary artery stent, non-biodegradable-polymer-coated - stenting system for coronary arteries, supplied pre-loaded onto an angioplasty balloon catheter. the xience prime ll is intended to deliver and deploy a balloon-expandable, drug coated metal stent in the de novo and restenotic native coronary arteries. five different stent diameters in two different lengths are available. drug dose (micrograms) varies with stent size. indicated for improving coronary luminal diameter in the following: patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions; for restoring coronary flow in patients experiencing acute myocardial infarction who present within 12 hours of symptom onset; for the treatment of patients with concomitant diabetes, acute coronary syndrome, due vessel lesions (two lesions in two different epicardial vessels), lesions residing within small coronary vessels (rvd equal to or < 2.77 mm), and in lesions where treatment results in the jailing of side branches (lesion with a side branch < 2 mm in diameter or equal

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott vascular division of abbott medical australia pty ltd - 56284 - drug-eluting coronary artery stent, non-biodegradable-polymer-coated - stenting system for coronary arteries, supplied pre-loaded onto an angioplasty balloon catheter. the xience prime sv is intended to deliver and deploy a balloon expandable, drug coated metal stent in the de novo and restenotic native coronary arteries. six different lengths of 2.25mm diameter stent are available. drug dose (micrograms) varies with stent length. the xience prime sv everolimus eluting coronary stent system is indicated for improving coronary luminal diameter in the following: " patients with symptomatic ischemic heart disease due to discrete de novo native coronary ; artery lesions. " for restoring coronary flow in patients experiencing acute myocardial infarction who present within 12 hours of symptom onset. " for the treatment of patients with concomitant diabetes, acute coronary syndrome, dual vessel ; lesions (two lesions in two different epicardial vessels), lesions residing within small coronary ; vessels; lesions where treatment results in the jailing of side branches (lesi

Singapore - English - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - loratadine; pseudoephedrine - tablet, sugar coated - 10 mg - loratadine 10 mg; pseudoephedrine 240 mg

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

apvma permit - sodium percarbonate(880g/kg) - parasiticide

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - oxymetazoline hydrochloride 0.5 mg/ml - nasal spray solution - 500 mcg/ml - active: oxymetazoline hydrochloride 0.5 mg/ml excipient: benzalkonium chloride benzyl alcohol dibasic sodium phosphate disodium edetate dihydrate dispersible cellulose glycerol lemon flavour 862.015 monobasic sodium phosphate monohydrate polyethylene glycol 1450 povidone purified water - symptomatic relief of nasal and nasopharyngeal congestion associated with the common cold and flu, hayfever and sinusitis, and to facilitate visual intranasal examination. by decreasing congestion around the eustachian tube ostia, it may be useful in the adjunctive treatment of congestion associated with middle ear conditions.